Antibody Response and Safety of ChAdOx1-nCOV (Covishield) in Patients with Cirrhosis: A Cross-Sectional, Observational Study

INTRODUCTION: Patients with cirrhosis have a higher risk of severe COVID-19 and mortality and are high-priority patients for vaccination. However, cirrhotics were excluded from the phase 2/3 vaccine trials. Hence, we aimed to assess the antibody response and safety of Covishield (ChAdOx1nCoV-19) amo...

Descripción completa

Detalles Bibliográficos
Autores principales: Singh, Amandeep, De, Arka, Singh, Mini P., Rathi, Sahaj, Verma, Nipun, Premkumar, Madhumita, Taneja, Sunil, Duseja, Ajay, Singh, Virendra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9510448/
https://www.ncbi.nlm.nih.gov/pubmed/36156752
http://dx.doi.org/10.1007/s10620-022-07641-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9510448/
https://www.ncbi.nlm.nih.gov/pubmed/36156752
http://dx.doi.org/10.1007/s10620-022-07641-2

Ejemplares similares